TUMOR BIOLOGY AND MICROENVIRONMENT (TBM) ? ABSTRACT The Tumor Biology and Microenvironment (TBM) Program is a translational science program that aims to discover the cellular and molecular determinants that drive the initiation and progression of cancers through interactions with their microenvironments and develop and test innovative diagnostic and treatment strategies. This highly integrated Program includes 37 members from 13 departments and 4 schools at Wayne State University. TBM Program members, who conduct basic, preclinical, and clinical research, receive $4,468,183 in peer reviewed, cancer-related grant support, of which $1,943,419 is from the NCI. The TBM Program is organized along three major themes. The goal of the first theme is to explore biological processes that mediate the phenotypical plasticity, proliferation, and survival of tumor cells. Translational research is conducted to evaluate the potential clinical application of these molecular determinants as tumor markers and/or therapeutic targets. The second theme investigates mechanisms that enable tumor cells to overcome external barriers during invasion and metastasis. Our investigators assess the importance of factors that control extracellular proteolysis and signaling mechanisms that are being used by tumor cells to adapt to and subvert the microenvironment at primary and metastatic sites. The objective of the third theme is to develop new strategies to engage the immune system as powerful defenses against cancer. Research activities include the development of immune modulators and novel vehicles to optimally deliver immunotherapeutics, as well as the use of state-of-the art imaging modalities for monitoring the success to tumor immunotherapy. The TBM Program is led by Dr. Kay-Uwe Wagner as Program Leader and Dr. Asfar Azmi as Program Co-Leader. The Leader and Co-Leader are new since the last competitive renewal. All members of the TBM Program actively collaborate with members of the MI, MT, and PSDR Programs at KCI. Of the 484 manuscripts published between December 2015 and November 2019, 41% and 44% were intra- and inter-programmatic, respectively, and 61% were multi-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088976
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Mitrea, Cristina; Wijesinghe, Priyanga; Dyson, Greg et al. (2018) Integrating 5hmC and gene expression data to infer regulatory mechanisms. Bioinformatics 34:1441-1447
Ma, Huiyan; Ursin, Giske; Xu, Xinxin et al. (2018) Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis. Breast Cancer Res 20:5
Luca, Francesca; Kupfer, Sonia S; Knights, Dan et al. (2018) Functional Genomics of Host-Microbiome Interactions in Humans. Trends Genet 34:30-40
Simon, Michael S; Beebe-Dimmer, Jennifer L; Hastert, Theresa A et al. (2018) Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Cancer 124:1798-1807
Bock, Cathryn H; Jay, Allison M; Dyson, Gregory et al. (2018) The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 167:741-749
Hastert, T A; de Oliveira Otto, M C; Lê-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440
Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :
Mittal, Sandeep; Klinger, Neil V; Michelhaugh, Sharon K et al. (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128:414-421
Park, Hyo K; Schildkraut, Joellen M; Alberg, Anthony J et al. (2018) Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control 29:1081-1091
Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26

Showing the most recent 10 out of 826 publications